title: Antiangiogenic therapy for glioblastoma.
abstract: Glioblastomas are among the most vascular tumors due to the expression of a variety of proangiogenic factors. New drug regimens are being developed to target angiogenesis in an attempt to arrest tumor growth. In particular, the vascular endothelial growth factor (VEGF) pathway has been a prime drug target. Preliminary results with anti-VEGF agents have been promising with prolonged progression-free survival reported. In addition, the antipermeability effects of anti-VEGF agents have important consequences for tumor imaging and for patient quality of life by decreasing corticosteroid dependence. Unfortunately, the response to anti-VEGF therapy is transient, and the majority of patients eventually relapsed, so more work is needed to understand the mechanisms of tumor escape.
authors.affiliation: Department of Neurology, Massachusetts General Hospital Cancer Center, Boston, MA, USA. egerstner@partners.org
authors.forename: Elizabeth R
authors.initials: ER
authors.lastname: Gerstner
authors.forename: Tracy T
authors.initials: TT
authors.lastname: Batchelor
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D005909:Glioblastoma / Q000098:blood supply* / Q000188:drug therapy*; D006801:Humans; D008279:Magnetic Resonance Imaging; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A